Federico Zambon

Federico studied at the University of Padua in Italy for his Undergraduate Degree in Molecular Biology and his Master Degree in Health Biology. He then joined the laboratory of Professor Wade-Martins in the Department of Physiology, Anatomy and Genetics at the University of Oxford. For his DPhil, Federico studied α-Synuclein pathology in Parkinson's disease using iPSC-derived dopaminergic neurons. He then moved to University College London in the laboratory of Prof Michael Duchenne as a postdoc, to study GBA1 mutations and their effect on mitochondrial function and homeostasis using iPSC-derived dopaminergic neurons.

In 2018, Federico joined Oxford Biomedica, a lentiviral-based gene therapy company developing therapies for neurodegenerative disorders, macular degeneration and liver metabolic disease, before returning to the University of Oxford in 2024 to join the Institute of Development & Regenerative Medicine in the team lead by Associate Professor Carlo Rinaldi.